Clinical trials: Multiple Sclerosis
Relapsing Multiple Sclerosis
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
Primary Objective: To determine the long-term safety and tolerability of SAR442168 in RMS participants Secondary Objective: To evaluate efficacy of SAR442168 on disease activity, assessed by clinical and imaging methods
- Trial name
- NCT03996291
- Testing
- Tolebrutinib
- Where
- 37 sites in United States, Canada and 7 more
- Volunteers
- 125 people
- Sponsor
- Sanofi
Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS)
A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS)
PoNS therapy is a rehabilitation program that uses the PoNS device in conjunction with individualized physical exercise. This is an outcome research open label observational interventional multi-center study investigating the…
- Trial name
- PoNSTEP (NCT05437276)
- Testing
- PoNS®
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Helius Medical Inc
Relapsing-remitting Multiple Sclerosis
Extension Study of MT-1303
To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT01890655
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 17 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 367 people
- Sponsor
- Tanabe Pharma Corporation
Multiple Sclerosis
Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis
The goal of this clinical trial is to learn if intravenous infusion of allogeneic mesenchymal stem cell (MSC)-derived exosomes can slow disability progression and improve neurological function in adults with progressive multiple…
- Trial name
- NCT07146087
- Testing
- MSC-Derived Exosomes
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Biocells Medical
Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple…
- Trial name
- NCT02273635
- Testing
- Andrographolides
- Where
- Chile
- Volunteers
- 68 people
- Sponsor
- Innobioscience SpA
Relapsing Remitting Multiple Sclerosis
Fingolimod Effect on Cytokine and Chemokine Levels
The main purpose of this study was to measure the serum levels of cytokines and chemokines that are known to increase during multiple sclerosis relapses.
- Trial name
- NCT02373098
- Testing
- Fingolimod 0.5 mg
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
The primary objective of this study is to estimate the incidence of Anti-Natalizumab Antibodies (ANAs) in the cohort of natalizumab-naïve and other MS monoclonal antibody (mAb)-naive participants who start receiving natalizumab…
- Trial name
- NCT05925049
- Testing
- Natalizumab
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Biogen
Multiple Sclerosis
Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS
The purpose of this study is to learn about the pharmacokinetics and pharmacodynamics of RPC1063 in RMS.
- Trial name
- NCT02797015
- Testing
- RPC1063
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Celgene
Relapsing-remitting Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)
- Trial name
- FREEDOMS (NCT00289978)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg
- Where
- 115 sites in Australia, Belgium and 17 more
- Volunteers
- 1,272 people
- Sponsor
- Novartis
Multiple Sclerosis (MS)
An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis
In collaboration with the Mercy MS Achievement Center, Lumos Labs is proposing an open-label, 12-month pilot study of computerized cognitive training as part of the cognitive wellness program in order to evaluate (1) the user…
- Trial name
- NCT02612935
- Testing
- Lumosity
- Volunteers
- 88 people
- Sponsor
- Lumos Labs, Inc.
Progressive Multiple Sclerosis
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS.
- Trial name
- BOBCAT (NCT07139743)
- Testing
- Obecabtagene autoleucel (obe-cel)
- Where
- 7 sites in United States, Spain and 1 more
- Volunteers
- 24 people
- Sponsor
- Autolus Limited
Multiple Sclerosis, Relapsing-remitting
A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis
The primary purpose of this study is to evaluate the overall safety and efficacy of Tecfidera (Dimethyl Fumarate) as an oral treatment for Korean participants with relapsing-remitting multiple sclerosis (MS) under routine…
- Trial name
- NCT05366036
- Testing
- No Intervention
- Where
- 20 sites in South Korea
- Volunteers
- 172 people
- Sponsor
- Eisai Korea Inc.
Multiple Sclerosis
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
The primary objective of the study is to evaluate the safety of natalizumab use in the pediatric multiple sclerosis (MS) population.
- Trial name
- NCT02137109
- Testing
- natalizumab
- Volunteers
- 400 people
- Sponsor
- Biogen
Multiple Sclerosis
Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis
The purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (SVF), has on the quality of life of people with…
- Trial name
- NCT02157064
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- StemGenex
Multiple Sclerosis
Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis
The aim of this study is the development of novel telemedical examination methods based on sensor-based gait analysis in patients with multiple sclerosis (MS).
- Trial name
- MSgoesHome (NCT04771858)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medical Valley Digital Health Application Center GmbH
Multiple Sclerosis
Canadian Avonex PEN Productivity Study
This study is primarily designed to evaluate the impact of AVONEX PEN autoinjector on work capacity of participants with multiple sclerosis (MS) starting on this device.
- Trial name
- CAPPS (NCT01489748)
- Where
- Canada
- Volunteers
- 111 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
The purpose of this single visit extension study is to explore immune status in RRMS patients treated for at least 48 months with fingolimod.
- Trial name
- NCT02720107
- Testing
- fingolimod
- Where
- 26 sites in Germany
- Volunteers
- 133 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Forms of Multiple Sclerosis
Plegridy Observational Program
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term…
- Trial name
- POP (NCT02230969)
- Testing
- peginterferon beta-1a
- Where
- 152 sites in United States, Australia and 12 more
- Volunteers
- 1,208 people
- Sponsor
- Biogen
Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia
Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.
This is a Phase 1, open-label, 3-period study to determine radiprodil's potential to act as a perpetrator of cytochrome P-450 (CYP) metabolic pathways and transporter pathways.
- Conditions
- Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia, Other Neurological Disorders
- Trial name
- NCT06975605
- Testing
- Radiprodil + co-administered drugs
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GRIN Therapeutics, Inc.
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
The primary objective(s) of the study is to evaluate the impact of exposure to SC Peginterferon beta-1a or IM Interferon beta-1a before and during pregnancy on pregnancy outcome in female participants who had registered in the…
- Trial name
- NCT04655222
- Testing
- Interferon Beta Therapy
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Biogen